Abstract
Pituitary adenylyl cyclase activating polypeptide (PACAP) is a neuropeptide with great neuroprotective effects and remarkable therapeutic potential. PACAP activates several cellular pathways to exert its protective effects. Emerging evidence shows that PACAP can modify the levels and activity of cell cycle components involved in neurodegeneration to protect neurons from death. Cell cycle is a highly regulated process that controls the balance between proliferation, differentiation and death of every cell in the body. Aberrant expression and function of components of the cell cycle machinery have been linked to neurodegenerative diseases, in which different types of neuronal cells become dysfunctional and die in response to toxic insults. Since neurons are postmitotic cells, re-entry into the cell cycle has been shown to be pathological and contributes to the process of neurodegeneration. Moreover, an increasing number of studies highlight the importance of the role of cell cycle components outside the cell cycle and their involvement in neurodegenerative disorders. Here, we discuss the pleiotropic effects of PACAP on cell cycle machinery and the implication for the treatment of neurodegenerative diseases.
Keywords: Neurodegeneration, cell cycle re-entry, pituitary adenylyl cyclase activating polypeptide (PACAP), apoptosis, therapy, adult neurons.
Current Pharmaceutical Design
Title:Pituitary Adenylyl Cyclase Activating Polypeptide (PACAP) Signaling and the Cell Cycle Machinery in Neurodegenerative Diseases
Volume: 24 Issue: 33
Author(s): María José Polanco*Maria Pennuto*
Affiliation:
- Laboratory of Pharmacology and Toxicology, Department of Pharmaceutical and Health Sciences, Faculty of Pharmacy, San Pablo CEU University, Madrid,Spain
- Department of Biomedical Sciences, University of Padova, 35100 Padova,Italy
Keywords: Neurodegeneration, cell cycle re-entry, pituitary adenylyl cyclase activating polypeptide (PACAP), apoptosis, therapy, adult neurons.
Abstract: Pituitary adenylyl cyclase activating polypeptide (PACAP) is a neuropeptide with great neuroprotective effects and remarkable therapeutic potential. PACAP activates several cellular pathways to exert its protective effects. Emerging evidence shows that PACAP can modify the levels and activity of cell cycle components involved in neurodegeneration to protect neurons from death. Cell cycle is a highly regulated process that controls the balance between proliferation, differentiation and death of every cell in the body. Aberrant expression and function of components of the cell cycle machinery have been linked to neurodegenerative diseases, in which different types of neuronal cells become dysfunctional and die in response to toxic insults. Since neurons are postmitotic cells, re-entry into the cell cycle has been shown to be pathological and contributes to the process of neurodegeneration. Moreover, an increasing number of studies highlight the importance of the role of cell cycle components outside the cell cycle and their involvement in neurodegenerative disorders. Here, we discuss the pleiotropic effects of PACAP on cell cycle machinery and the implication for the treatment of neurodegenerative diseases.
Export Options
About this article
Cite this article as:
Polanco José María *, Pennuto Maria*, Pituitary Adenylyl Cyclase Activating Polypeptide (PACAP) Signaling and the Cell Cycle Machinery in Neurodegenerative Diseases, Current Pharmaceutical Design 2018; 24 (33) . https://dx.doi.org/10.2174/1381612825666181127102311
DOI https://dx.doi.org/10.2174/1381612825666181127102311 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nutraceuticals against Neurodegeneration: A Mechanistic Insight
Current Neuropharmacology Editorial [Hot topic: Parkinsons Disease (Guest Editor: Jurgen Dinges)]
Current Topics in Medicinal Chemistry Genetics of Alzheimer's Disease and Frontotemporal Dementia
Current Molecular Medicine Immunological Approaches to Prevent Neuronal Apoptosis During Neuroinflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Therapeutic Potential of Hepatocyte Growth Factor for Treating Neurological Diseases
Current Drug Therapy Potential for Treatment of Neurodegenerative Diseases with Natural Products or Synthetic Compounds that Stabilize Microtubules
Current Pharmaceutical Design Multiple Sclerosis Therapy Monitoring Based on Gene Expression
Current Pharmaceutical Design State of the Art Clinical Efficacy and Safety Evaluation of N-Acetylcarnosine Dipeptide Ophthalmic Prodrug. Principles for the Delivery, Self-Bioactivation, Molecular Targets and Interaction with a Highly Evolved Histidyl-Hydrazide Structure in the Treatment and Therapeutic Management of a Group of Sight-Threatening Eye Diseases
Current Clinical Pharmacology Review of Synthesis, Biological Assay and QSAR Studies of β-Secretase Inhibitors
Current Computer-Aided Drug Design Editorial (Thematic Issue: Special Issue in Memory of Prof. Dr. Luis Eduardo Diaz: Current Topics in Pharmaceutical Biotechnology)
Current Pharmaceutical Biotechnology Editorial (Thematic Issue: Ultrasonic Vocalizations in Rats: A Tool for the Investigation of Psychoactive Drugs and Neuropsychiatric Conditions)
Current Neuropharmacology Current Issues in the Use of fMRI-Based Neurofeedback to Relieve Psychiatric Symptoms
Current Pharmaceutical Design Recent Patents in Diagnosis and Treatment for Inborn Errors of Metabolism
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Marine Sesterterpenes: An Overview
Current Organic Chemistry Alzheimer’s Disease And Type 2 Diabetes: Exploring The Association To Obesity And Tyrosine Hydroxylase
CNS & Neurological Disorders - Drug Targets The Multifactorial Nature of Alzheimer's Disease for Developing Potential Therapeutics
Current Topics in Medicinal Chemistry The Role of Oxidative Stress in Depressive Disorders
Current Pharmaceutical Design Selective COX-1 Inhibition: A Therapeutic Target to be Reconsidered
Current Medicinal Chemistry Glia: An Important Target for Anti-Inflammatory and Antidepressant Activity
Current Drug Targets Nicotinamide as a Foundation for Treating Neurodegenerative Disease and Metabolic Disorders
Current Neurovascular Research